Inflammatory bowel diseases (IBD) are a growing global concern, with current treatments—primarily anti-inflammatory drugs and biologics—facing limitations such as side effects, high cost, resistance, and low patient compliance.

This study proposes a nutraceutical-based alternative by developing food-grade Eudraguard® Biotic/Control microparticles (MPs) encapsulating trans-resveratrol (RSV), the isoform with superior anti-inflammatory activity. Two green encapsulation methods, emulsion solvent evaporation (ESE) and solvent evaporation (SE), were employed to protect RSV from degradation and achieve sustained colonic release. Solid-state characterization and in vitro studies assessed stability (under UV, light, heat, and long-term storage), dissolution behavior, and release kinetics. Both techniques effectively preserved RSV's trans-isomer and minimized premature release in the gastric and intestinal phases, enabling targeted and prolonged delivery (up to 24 h) in the colon. Further in vitro and in vivo investigations will assess the safety and therapeutic efficacy of these systems.